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Case ReportDrug-induced Thrombotic Microangiopathy During
Maintenance Treatment in a Patient With Multiple
Myeloma
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Correspondence: María-Victoria Mateos (e-mail: mvmateos@usal.es).Multiple myeloma (MM) is still considered an incurable disorder to gene mutation, mutations of the complement pathway,
despite the important advances in therapies in the last 10 years.1
One of these improvements is associated with the introduction of
maintenance treatment for younger patients after autologous
stem cell transplantation. Lenalidomide is known to prolong
progression-free survival and overall survival without any
significant increase in toxicity, leading to its approval for use.2
Other drugs, such as ixazomib, an oral proteasome inhibitor that
is well tolerated and has only mild adverse effects, are being
investigated for maintenance treatments.3 Here, we describe a
serious complication that could be associated with this group of
drugs: a drug-induced thrombotic microangiopathy (TMA) that,
although rare, can be life threatening if not diagnosed at an early
stage.
TMA is clinically defined by the concurrent appearance of
microangiopathic hemolytic anemia, thrombocytopenia, and
organ injury caused by vascular damage that is manifested as
arteriolar and capillary thrombosis. As knowledge of the
pathogenesis has evolved, 9 disorders have been described and
categorized as hereditary or acquired disorders. Hereditary
disorders include those mediated by ADAMTS13 deficiency dueFunding/support: None.
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metabolism, and coagulation. Acquired disorders include those
mediated by ADAMTS13 deficiency arising from antibody
inhibition, Shiga-toxin, drugs (an immune reaction or a toxic
dose), and alteration of complement pathway (such as the
antibody inhibition of complement factor H).4 Below, we present
a patient diagnosed with drug-mediated TMA during mainte-
nance treatment with ixazomib.
A 55-year-old woman with a history of MM was admitted to
the emergency room due to a digestive hemorrhage with
significant hemodynamic and analytic repercussions. The patient
had been treated as part of the Spanish Myeloma Group GEM12
clinical trial with bortezomib, lenalidomide, and dexamethasone,
followed by autologous stem cell transplantation, after which she
attained stringent complete remission (sCR) was achieved. She
was included in another clinical trial (GEM14MAIN) for
maintenance therapy with ixazomib (4mg on days 1, 8, and
15 of 28-day cycles), lenalidomide (15mg daily on days 1–21),
and dexamethasone (20mg on days 1–4 and 9–12) and remained
in sCR after 11 months.
Upon admission to the emergency room, her initial blood
analysis revealed normocytic hyperchromic anemia (hemoglobin
75g/L) with a low reticulocyte count (25109/L), and deep
thrombocytopenia (1109/L) with low immature platelet
fraction, both suggesting a central origin. However, a blood
smear was analyzed, which revealed a 12% schistocytes count.
These findings, associated with renal failure (creatinine 43.4mg/
L), elevated bilirubin (12.8mg/L), high lactate dehydrogenase
(869U/L), consumed haptoglobin, and a negative direct Coombs
test, were consistent with a diagnosis of TMA.
An endoscopic investigation of the origin of the hemorrhage
led to a diagnosis of erosive duodenitis. The condition was treated
with proton-pump inhibitors, which resolved the bleeding.
Given the clinical suspicion of thrombotic thrombocytopenic
purpura, initial management included plasma exchange therapy,
with fresh-frozen plasma, and the administration of glucocorti-
coids 1mg/kg per day, as well as platelet transfusion due to active
bleeding. Treatment with ixazomib and lenalidomide was
discontinued. Despite these measures, the thrombocytopenia
persisted and the renal failure worsened, the patient requiring
dialysis after 72hours.
Screening for thrombotic thrombocytopenic purpura and
hemolytic uremic syndrome included testing for ADAMTS13
activity, which had a normal level of 110%, and antibody
Figure 1. Improvement of creatinine, hemoglobin and platelet count after eculizumab initiation.
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infectious diseases and a stool culture with Shiga toxin-producing
Escherichia coli gave negative results. As active disease is known to
be a cause of TMA, the MM status was re-evaluated, which
confirmed the sCR.4,5 Autoimmune studies including complement
factors C3, C4, and C5 showed an abnormally low fraction of C3
andC4 and an elevatedC5 fraction. Even though, classically, these
findings were consistent with a diagnosis of complement-mediated
hemolytic uremic syndrome; there is now evidence that C3, C5a,
andC9 are not suitable for diagnosis because abnormal circulating
levels are found in only around 50% of the patients.6We searched
for possible triggers in our patient, but found only proteasome
inhibitors to be a possible cause.7–10 She was therefore diagnosed
with drug-mediated TMA.
Proteasome inhibitors are known to be a cause of TMA,7–10 but,
there are few published cases. The mechanisms by which TMA
occurs have not so far been identified. Some hypotheses propose
that there is both immune-mediated and dose-dependent damage.
One of the best-studied potential mechanisms is microvascular
damage mediated by inhibition of vascular endothelium growth
factor, which is essential for the functional integrity of the
glomerular endothelium. There are few therapeutic options,
support therapy and drug discontinuation being the most widely
accepted.4,8 In the last few years, cases of TMA not responding to
standard therapy have been published, and it has been suggested
that rescue treatment with eculizumab, an inhibitor of the
complement alternative pathway, may be beneficial.9,11,12
Due to the catastrophic evolution of the disease in our patient
despite support therapy, treatment with eculizumab was started.
This monoclonal antibody binds with high affinity to C5
complement protein and blocks the generation of proinflamma-
tory C5a.13 The dose was 900mgweekly for 4 weeks followed by
maintenance therapy of 1200mg every 2 weeks, as used for
complement-mediated TMA. Renal impairment was alleviated
after the first dose, and the patient achieved independence from
hemodialysis after the 2nd dose. From the 6th dose onward,
hemoglobin and platelet count gradually increased, achieving
until normal values by the 10th administration. Figure 1 shows2
the evolution of hemoglobin, platelets, and creatinine after the
initiation of treatment with eculizumab.
Reaching an accurate diagnosis of this case was challenging.
Since the complement factors were altered, we initially concluded
that the patient was suffering a complement-mediated TMA.
However, literature review showing complement factor alter-
ation is very nonspecific, and considering the negative result of
genetic tests for complement mutations, and the possible
association with drugs, prompted us to consider a diagnosis of
drug-mediated TMA.
There is no evidence of there being an optimal time to stop
therapy with eculizumab. Some studies, with a small number of
patients with complement-mediated TMA, have concluded that
treatment may be withdrawn from patients with a good initial
response and those with mutations like CD46, who have a lower
risk of recurrence.14 There are no useful parameters in the follow-
up, since the levels of C3, C5, and C9 cannot be reliably
measured.6 Given the complete response we decided to stop
treatment after 11 cycles; especially since other data suggest that,
should the disease recur, reintroduction of eculizumab is equally
effective.14,15 At the time of writing, the patient maintains her
complete response to both MM and TMA.
Although drug-mediated TMA is a very rare condition, it is a
potentially fatal disorder if therapy is not initiated early on. For
this reason, prompt suspicion and diagnosis, together with the
identification of a potential trigger, are keys to achieving a good
outcome. Eculizumab might be an option for patients who do not
respond to the initial therapy.
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